Generic Name and Formulations:
Measles, mumps, rubella, and varicella viruses live, attenuated; lyophilized pwd for SC inj after reconstitution; contains neomycin (trace), human albumin; preservative-free.
Merck & Co., Inc.
Indications for PROQUAD:
Measles, mumps, rubella, and varicella immunization; may be used if a 2nd dose of measles, mumps, rubella, and varicella vaccine is needed.
Give SC in deltoid area or upper anterolateral thigh. <12 months or ≥13yrs: not recommended. 12 months–12yrs: 1 dose of 0.5mL. If a 2nd dose is needed, give at 4–6yrs.
Egg, gelatin, or neomycin hypersensitivity. Blood dyscrasias. Leukemia, lymphoma, or other bone marrow or lymphatic malignancy. Primary or acquired immunodeficiency. Family history of congenital or hereditary immunodeficiency. Immunosuppressant therapy. Active untreated tuberculosis. Fever >101.3°F. Pregnancy (Cat.X); avoid pregnancy for 3 months after vaccination.
Have epinephrine inj (1:1000) available. History of febrile convulsions or cerebral injury. Thrombocytopenia. Avoid contact with high-risk individuals susceptible to varicella for 6 weeks after vaccination. Post-exposure prophylaxis for measles, mumps, rubella, or varicella. HIV-infected children. Contains albumin; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease). Nursing mothers: not recommended.
Immunosuppressants (see Contraindications). Avoid salicylates for 6 weeks after vaccination. Defer vaccination for at least 3 months after blood or plasma transfusions or immune globulins. Avoid immune globulin administration for 1 month after vaccination. Separate dosing of measles-containing vaccine by 1 month. If 2nd dose of varicella-containing vaccine needed, separate by 3 months. Concomitant other vaccines: see full labeling. May interfere with tuberculin skin test.
Inj site reactions, fever, irritability, rash; others.
Report adverse events to VAERS by calling (800) 822-7967.
Single-dose vials—10 (w. diluent)
Neurology Advisor Articles
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Patients With Multiple Sclerosis Face Greater Infection Risk
- Fingolimod Compared With Glatiramer Acetate in Head-to-Head MS Study
- Lower Relapse Risk and Disability Progression With Oral DMT in Treatment-Naive RRMS
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure
- OnabotulinumtoxinA Injections Reduce Frequency of Cluster Headaches
- Aetna-CVS Merger Approved
- Trump to Sign Bills Lifting Drug Price 'Gag Orders' on Pharmacists
- Pediatric Migraine: Evidence-Based Alternative Management